GlassScriptPhysician profile
Betul A Hatipoglu
NPI 1245343862
$12,261.81
in general payments reported to CMS, 2019-2025
27 companies · $6,501 in 2025
The $6,501 reported for 2025 was more than what 88% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,134 · 2021: $183 · 2022: $619 · 2023: $473 · 2024: $352 · 2025: $6,501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,325 · Food and Beverage: $1,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,325.00 |
| Food and Beverage | $1,001.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $6,500.36 | 2021-2025 | Mounjaro |
| Merck Sharp & Dohme LLC | $4,037.38 | 2019 | |
| Novo Nordisk INC | $619.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $123.17 | 2022-2024 | Gvoke Hypopen, Recorlev |
| Novartis Pharmaceuticals Corporation | $104.29 | 2022-2025 | |
| Amarin Pharma, INC. | $99.16 | 2021-2023 | |
| Dexcom, INC. | $87.41 | 2022-2023 | Dexcom G6 Transmitter |
| Grt US Holding, INC. | $87.18 | 2022 | |
| Corcept Therapeutics | $59.72 | 2024 | Korlym |
| Medtronic, INC. | $56.56 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.75 | 2022-2023 | Jardiance |
| Abbvie INC. | $45.69 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $43.24 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $42.17 | 2022-2023 | Farxiga |
| Recordati_rare_diseases_inc. | $39.79 | 2022-2023 | Isturisa, Signifor Lar |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $37.83 | 2025 | Nexletol |
| Amryt Pharma Holdings LTD | $35.63 | 2023 | Mycapssa |
| Amphastar Pharmaceuticals, INC. | $30.86 | 2025 | |
| Beta Bionics, INC. | $27.52 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Eusa Pharma (US) LLC | $24.90 | 2022 | |
| Abbott Laboratories | $24.34 | 2022 | |
| Amgen INC. | $21.89 | 2024 | Prolia, Evenity |
| Glaxosmithkline, LLC. | $18.99 | 2025 | Shingrix, Arexvy |
| Ascendis Pharma Endocrinology INC | $15.79 | 2023 | |
| Azurity Pharmaceuticals, INC. | $15.21 | 2023 | Adthyza |
| Neurocrine Biosciences, INC. | $13.91 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Betul Hatipoglu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.